联合检测抑制素A、CA125与CA153在卵巢癌中的表达及临床意义

Clinical Significance of Combined Detection of INH-A,CA125 and CA153 Levels in Patients with Ovarian Carcinoma

目的探讨联合检测血清抑制素A(INH-A)、CA125与CA153水平对卵巢癌早期诊断的价值。方法采用全自动化学发光免疫分析法(CLIA)检测卵巢癌组40例,卵巢良性疾病组30例,对照组30名健康女性的血清INH-A、CA125与CA153水平。结果卵巢癌组血清INH-A、CA125与CA153水平明显高于卵巢癌组和卵巢良性疾病组,差异有统计学意义(P<0.05);三项标志物的阳性率分别为52.5%,60.0%,72.5%,三项联合检测的阳性率为82.5%。卵巢癌组血清INH-A水平高于卵巢良性疾病组和对照组,提示INH-A异常表达可能与卵巢癌的发生密切相关。结论 INH-A可能作为诊断卵巢癌的一项肿瘤标志物,联合检测有助于早期诊断卵巢癌以及病情监测。

Objective To explore the early diagnostic values of combined detection of serum INH-A, CA125 and CA153 levels in patients with ovarian carcinoma. Methods The serum levels of INH-A, CA125 and CA153 of 40 patients with ovarian cancer, 30 patients with benign ovarian disease and 30 healthy women controls were measured by CLIA. Results The serum INH-A, CA125 and CA153 levels and positive rate in patients with ovarian cancer were significantly higher than that of in patients with benign ovarian tumor and healthy controls （P 〈0. 05）. The positive rates of INH-A, CA12 5and CA153 in patients with ovarian cancer were 52.5% , 60.0% and 72.5 %, respectively. The positive rate of three markers,combined detection was 82.5%. The INH-A levels in patients with ovarian cancer were higher than that in the control group. The abnormal expression of INH- A could be closely related to the occurrence of ovarian cancer, and might be used as a tumor marker for diagnosis of ovarian cancer. Conclusion The joint detection of serum INH-A, CA125, and CA153 levels may be helpful for early diagnosis of ovarian cancer and disease monitoring.